Flupirtine
(Synonyms: 氟吡汀,D 9998) 目录号 : GC36060
An activator of Kv7 channels
Cas No.:56995-20-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Flupirtine is an activator of voltage-gated potassium channel 7 (Kv7/KCNQ).1,2,3 It induces relaxation of preconstricted pulmonary arteries isolated from wild-type and serotonin transporter-overexpressing (SERT+) mice.2 Flupirtine (30 mg/kg per day) decreases mean right ventricular pressure and right ventricular hypertrophy in hypoxia-induced and SERT+ mouse models of pulmonary arterial hypertension. It increases the paw withdrawal threshold in a rat model of streptozotocin-induced diabetic neuropathy when administered at a dose of 10 mg/kg and increases paw withdrawal latency in a rat model of carrageenan-induced paw inflammation when used in combination with morphine.3 Flupirtine also indirectly antagonizes NMDA receptors via its effects on potassium channels.1,4
1.Devulder, J.Flupirtine in pain management: Pharmacological properties and clinical useCNS Drugs25(10)867-881(2010) 2.Morecroft, I., Murray, A., Nilsen, M., et al.Treatment with the Kv7 potassium channel activator flupirtine is beneficial in two independent mouse models of pulmonary hypertensionBr. J. Pharmacol.157(7)1241-1249(2009) 3.Goodchild, C.S., Kolosov, A., Tucker, A.P., et al.Combination therapy with flupirtine and opioid: Studies in rat pain modelsPain Med.9(7)928-938(2008) 4.Kornhuber, J., Bleich, S., Wiltfang, J., et al.Flupirtine shows functional NMDA receptor antagonism by enhancing Mg2+ block via activation of voltage independent potassium channelsJ. Neural Transm. (Vienna)106(9-10)857-867(1999)
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.286 mL | 16.4301 mL | 32.8601 mL |
| 5 mM | 0.6572 mL | 3.286 mL | 6.572 mL |
| 10 mM | 0.3286 mL | 1.643 mL | 3.286 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。